{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:11:45Z","timestamp":1757617905257,"version":"3.44.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:sec>\n            <jats:title>Hintergrund<\/jats:title>\n            <jats:p>Extrem hohe Baseline-PSA-Werte (bPSA) im Bereich von 100 bis \u2265\u202f1000\u202fng\/ml vor Beginn der systemischen Therapie stellen eine Herausforderung dar, da der Eindruck einer sehr ung\u00fcnstigen Prognose entstehen kann.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ziel der Arbeit<\/jats:title>\n            <jats:p>Wir untersuchten Einflussfaktoren auf das 5\u2011Jahres-Gesamt\u00fcberleben (5-JG\u00dc) und die Therapiemodalit\u00e4ten von Betroffenen mit bPSA-Werten von \u2265\u202f100\u202fng\/ml anhand retrospektiver Daten.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Material und Methoden<\/jats:title>\n            <jats:p>Aus einem kleineren initialen Kollektiv legten wir Items fest, die wir f\u00fcr eine Abfrage aus der Datenbank UroCloud nutzten. Dabei wurden insgesamt 695\u00a0Betroffene eingeschlossen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ergebnisse und Schlussfolgerung<\/jats:title>\n            <jats:p>F\u00fcr das gesamte Kollektiv ergab sich ein 5\u2011JG\u00dc von 68,5\u202f%\u202f\u00b1\u20092,7\u202f%. Der bPSA-Wert hatte in folgender Gruppierung signifikanten (<jats:italic>p<\/jats:italic>\u202f&lt;\u20090,001) Einfluss auf das 5\u2011JG\u00dc: 100\u2013149\u202fng\/ml, 150\u2013249\u202fng\/ml, 250\u2013649\u202fng\/ml, \u2265\u202f650\u202fng\/ml (5-JG\u00dc: 77,0\u202f%\u202f\u00b1\u20094,9\u202f% vs.\u00a076,9\u202f%\u202f\u00b1\u20094,5\u202f% vs.\u00a061,4\u202f% \u00b1\u202f6,0 vs.\u00a057,4\u202f%\u00b1\u202f6,1\u202f%). Ein Alter von \u2264\u202f70\u00a0Jahren gegen\u00fcber &gt;\u202f70\u00a0Jahren bei Erstdiagnose ergab einen signifikanten Unterschied bez\u00fcglich des 5\u2011JG\u00dc (5-JG\u00dc: 74,8\u202f% \u00b1\u202f3,5\u202f% vs.\u00a060,1\u202f% \u00b1\u202f4,4). Eine PSA-Response von &gt;\u202f90\u202f%, die in 79,0\u202f% der F\u00e4lle erreicht wurde, hatte signifikanten Einfluss auf das 5\u2011JG\u00dc gegen\u00fcber einer Response von \u2264\u202f90\u202f% (5-JG\u00dc: 73,5\u202f% \u00b1\u202f2,9\u202f% vs.\u00a048,6\u202f% \u00b1\u202f6,7\u202f%). Ebenso zeigte sich ein signifikanter Vorteil im 5\u2011JG\u00dc, wenn ein erster PSA-Nadir von &lt; 0,20\u202fng\/ml erreicht wurde (in 22,2\u202f% der F\u00e4lle), gegen\u00fcber einem ersten PSA-Nadir von \u2265 0,20\u202fng\/ml (5-JG\u00dc: 89,8\u202f% \u00b1\u202f3,3\u202f% vs.\u00a060,4\u202f% \u00b1\u202f3,5\u202f%). In 49,4\u202f% (<jats:italic>n<\/jats:italic>\u202f=\u2009343) der F\u00e4lle wurde als systemische Erstlinientherapie eine Androgendeprivationstherapie (ADT) als Monotherapie begonnen, \u00fcber den Zeitraum 1999\u20132023 sahen wir eine Zunahme an gestaffelten und initialen Kombinationstherapien. Die Untersuchung zeigt, dass ein extremer bPSA-Wert f\u00fcr sich kein Ausdruck einer ung\u00fcnstigen Prognose ist.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphic abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00120-025-02583-9","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:59:05Z","timestamp":1747645145000},"page":"803-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PSA im Extrembereich \u2013 Ausdruck einer infausten Prognose?","PSA in the extreme range\u2014an expression of an unfavorable prognosis?"],"prefix":"10.1007","volume":"64","author":[{"given":"Christian","family":"Dirscherl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd J.","family":"Schmitz-Dr\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Goebell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2583_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bju.13411","volume":"117","author":"M Ang","year":"2016","unstructured":"Ang\u00a0M, Rajcic\u00a0B, Foreman\u00a0D et\u00a0al (2016) Men presenting with prostate-specific antigen (PSA) values of over 100\u202fng\/mL. BJU Int 117:68\u201375","journal-title":"BJU Int"},{"key":"2583_CR2","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov\u00a0C, Albers\u00a0P, Herkommer\u00a0K et\u00a0al (2022) A randomized trial of risk-adapted screening for prostate cancer in young men\u2014Results of the first screening round of the PROBASE trial. Intl Journal of Cancer 150:1861\u20131869","journal-title":"Intl Journal of Cancer"},{"key":"2583_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s00120-015-3843-y","volume":"54","author":"R Berges","year":"2015","unstructured":"Berges\u00a0R, Ebert\u00a0T, Schafhauser\u00a0W et\u00a0al (2015) Versorgungsabbild zum Prostatakarzinom in DVPZ-Prostatazentren in Deutschland. Urologe 54:1546\u20131554","journal-title":"Urologe"},{"unstructured":"Berufsverband Der Deutschen Urologie e.\u202fV. (2023) Aufbruch in eine neue Dimension der Bereitstellung urologischer Versorgungsdaten. In:Berufsverband der Deutschen Urologie e.\u202fV. https:\/\/urologie-gestalten.de\/blog\/aufbruch-in-eine-neue-dimension-der-bereitstellung-urologischer-versorgungsdaten\/","key":"2583_CR4"},{"key":"2583_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/1557988315584376","volume":"11","author":"C Biddle","year":"2017","unstructured":"Biddle\u00a0C, Brasel\u00a0A, Underwood\u00a0W 3rd et\u00a0al (2017) Experiences of Uncertainty in Men With an Elevated PSA. Am J Mens Health 11:24\u201334","journal-title":"Am J Mens Health"},{"key":"2583_CR6","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1200\/JCO.2020.38.15_suppl.5541","volume":"38","author":"KN Chi","year":"2020","unstructured":"Chi\u00a0KN, Saad\u00a0F, Chowdhury\u00a0S et\u00a0al (2020) Prostate-specific antigen (PSA) kinetics in patients with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. JCO 38:5541\u20135541","journal-title":"JCO"},{"key":"2583_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cncr.24064","volume":"115","author":"TK Choueiri","year":"2009","unstructured":"Choueiri\u00a0TK, Xie\u00a0W, D\u2019amico\u00a0AV et\u00a0al (2009) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115:981\u2013987","journal-title":"Cancer"},{"key":"2583_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury\u00a0S, Bjartell\u00a0A, Agarwal\u00a0N et\u00a0al (2023) Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol 34:477\u2013485","journal-title":"Ann Oncol"},{"key":"2583_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein\u00a0JI, Egevad\u00a0L, Amin\u00a0MB et\u00a0al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a\u00a0New Grading System. Am J Surg Pathol 40:244\u2013252","journal-title":"Am J Surg Pathol"},{"key":"2583_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","volume":"69","author":"JI Epstein","year":"2016","unstructured":"Epstein\u00a0JI, Zelefsky\u00a0MJ, Sjoberg\u00a0DD et\u00a0al (2016) A Contemporary Prostate Cancer Grading System: A\u00a0Validated Alternative to the Gleason Score. Eur Urol 69:428\u2013435","journal-title":"Eur Urol"},{"key":"2583_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi\u00a0K, Foulon\u00a0S, Carles\u00a0J et\u00a0al (2022) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a\u00a0multicentre, open-label, randomised, phase\u00a03\u00a0study with a\u00a02 x 2 factorial design. Lancet 399:1695\u20131707","journal-title":"Lancet"},{"key":"2583_CR12","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1200\/JCO.2023.41.16_suppl.5070","volume":"41","author":"S Halabi","year":"2023","unstructured":"Halabi\u00a0S, Roy\u00a0A, Guo\u00a0SS et\u00a0al (2023) Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). JCO 41:5070\u20135070","journal-title":"JCO"},{"key":"2583_CR13","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","volume":"36","author":"LC Harshman","year":"2018","unstructured":"Harshman\u00a0LC, Chen\u00a0YH, Liu\u00a0G et\u00a0al (2018) Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J\u00a0Clin Oncol 36:376\u2013382","journal-title":"J Clin Oncol"},{"key":"2583_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4111\/kju.2012.53.9.607","volume":"53","author":"SY Hong","year":"2012","unstructured":"Hong\u00a0SY, Cho\u00a0DS, Kim\u00a0SI et\u00a0al (2012) Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer. Korean J Urol 53:607\u2013613","journal-title":"Korean J Urol"},{"key":"2583_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James\u00a0ND, Sydes\u00a0MR, Clarke\u00a0NW et\u00a0al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163\u20131177","journal-title":"Lancet"},{"key":"2583_CR16","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.clgc.2024.102162","volume":"22","author":"DVK Jehle","year":"2024","unstructured":"Jehle\u00a0DVK, Nguyen\u00a0N, Garza\u00a0MA et\u00a0al (2024) PSA Levels and Mortality in Prostate Cancer Patients. Clin Genitourin Cancer 22:102162","journal-title":"Clin Genitourin Cancer"},{"key":"2583_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00432-014-1612-8","volume":"140","author":"Y Kitagawa","year":"2014","unstructured":"Kitagawa\u00a0Y, Ueno\u00a0S, Izumi\u00a0K et\u00a0al (2014) Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a\u00a0Japanese large-scale prospective cohort study (J-CaP). J\u00a0Cancer Res Clin Oncol 140:673\u2013679","journal-title":"J Cancer Res Clin Oncol"},{"key":"2583_CR18","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"G van Leenders","year":"2020","unstructured":"Leenders\u00a0G van, Der Kwast\u00a0TH van, Grignon\u00a0DJ et\u00a0al (2020) The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma. Am J Surg Pathol 44:e87\u2013e99","journal-title":"Am J Surg Pathol"},{"unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2024) S3-Leitlinie Prostatakarzinom Langversion 7.0. AWMF-Registernummer: 043\u201322OL","key":"2583_CR19"},{"issue":"252","key":"2583_CR20","first-page":"e219","volume":"41","author":"B Lowentritt","year":"2023","unstructured":"Lowentritt\u00a0B, Pilon\u00a0D, Waters\u00a0D et\u00a0al (2023) Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A\u00a0retrospective cohort study. Urol Oncol 41(252):e219\u2013252.e227","journal-title":"Urol Oncol"},{"key":"2583_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","volume":"9","author":"P Mandel","year":"2023","unstructured":"Mandel\u00a0P, Hoeh\u00a0B, Wenzel\u00a0M et\u00a0al (2023) Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A\u00a0Systematic Review and Network Meta-analysis. Eur Urol Focus 9:96\u2013105","journal-title":"Eur Urol Focus"},{"issue":"viii273","key":"2583_CR22","first-page":"viii274","volume":"29","author":"N Matsubara","year":"2018","unstructured":"Matsubara\u00a0N, Chi\u00a0KN, Ozguroglu\u00a0M et\u00a0al (2018) LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO). Ann Oncol 29(viii273):viii274","journal-title":"Ann Oncol"},{"key":"2583_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"N Matsubara","year":"2020","unstructured":"Matsubara\u00a0N, Chi\u00a0KN, \u00d6zg\u00fcro\u011flu\u00a0M et\u00a0al (2020) Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase\u00a03 LATITUDE Study. Eur Urol 77:494\u2013500","journal-title":"Eur Urol"},{"issue":"6","key":"2583_CR24","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/bju.16449","volume":"134","author":"AS Merseburger","year":"2024","unstructured":"Merseburger\u00a0AS, Agarwal\u00a0N, Bjartell\u00a0A et\u00a0al (2024) Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. BJU International 134(6):982\u2013991","journal-title":"BJU International"},{"key":"2583_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1200\/JCO.2024.42.4_suppl.66","volume":"42","author":"AD Raval","year":"2024","unstructured":"Raval\u00a0AD, Chen\u00a0S, Littleton\u00a0N et\u00a0al (2024) Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): A\u00a0systematic review of real-world database studies. JCO 42:66\u201366","journal-title":"JCO"},{"key":"2583_CR26","volume-title":"Krebs in Deutschland f\u00fcr 2019\/2020","year":"2023","unstructured":"Robert Koch-Institut (Hrsg) (2023) Krebs in Deutschland f\u00fcr 2019\/2020, 14.\u00a0Aufl. (Ausgabe)","edition":"14"},{"key":"2583_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12894-019-0493-1","volume":"19","author":"U Ronningas","year":"2019","unstructured":"Ronningas\u00a0U, Fransson\u00a0P, Holm\u00a0M et\u00a0al (2019) Prostate-specific antigen (PSA) and distress:\u2014a\u00a0cross-sectional nationwide survey in men with prostate cancer in Sweden. BMC Urol 19:66","journal-title":"BMC Urol"},{"key":"2583_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","volume":"86","author":"F Saad","year":"2024","unstructured":"Saad\u00a0F, Hussain\u00a0MHA, Tombal\u00a0B et\u00a0al (2024) Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. European Urology 86:329\u2013339","journal-title":"European Urology"},{"key":"2583_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/jcm7120565","volume":"7","author":"T Sasaki","year":"2018","unstructured":"Sasaki\u00a0T, Sugimura\u00a0Y (2018) The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Na\u00efve Prostate Cancer Patients. J Clin Med 7:565","journal-title":"J Clin Med"},{"key":"2583_CR30","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith\u00a0MR, Hussain\u00a0M, Saad\u00a0F et\u00a0al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N\u00a0Engl J Med 386:1132\u20131142","journal-title":"N Engl J Med"},{"key":"2583_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney\u00a0CJ, Chen\u00a0YH, Carducci\u00a0M et\u00a0al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N\u00a0Engl J Med 373:737\u2013746","journal-title":"N Engl J Med"},{"issue":"3","key":"2583_CR32","first-page":"10","volume":"3","author":"IM Thompson","year":"2001","unstructured":"Thompson\u00a0IM (2001) Flare Associated with LHRH-Agonist Therapy. Rev Urol 3(3):10\u201314","journal-title":"Rev Urol"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02583-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02583-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02583-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:04:55Z","timestamp":1757171095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02583-9"}},"subtitle":["Eine \u00dcbersicht \u00fcber Verlauf und Therapie des Prostatakarzinoms mit PSA-Werten \n(prostataspezifisches Antigen) im drei- bis vierstelligen Bereich","A review of course and treatment of prostate cancer with prostate-specific antigen (PSA) values in the three-to-four-digit range"],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2583"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02583-9","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"21 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Dirscherl, T.\u00a0Ebert, B.J.\u00a0Schmitz-Dr\u00e4ger und P.J.\u00a0Goebell geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}